This is the drug that we recently gave a million dollar grant to help support and speed up it's development!  The mutation (H3K27 M)  is very common in DIPG, and common in midline and thalmic malignant gliomas, more so in younger GBM patients.  This experimental drug is in clinical trials. Check your pathology report to see if you have this mutation.  If you do, contact us and we can help you find a trial. (It is so common in DIPG that  no biopsy is needed to get into the trials for that tumor type - it is assumed they all have this)